Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4388294 | 0.85 | MEN1 (0.51) | MEN1KMT2ANR4A2PRKCAPRKCD | |
| SCHEMBL4410979 | 0.84 | MEN1 (0.48) | MEN1KMT2AFAAHNR4A2PRKCA | |
| SCHEMBL4395353 | 0.83 | MEN1 (0.45) | MEN1KMT2AFAAHNR4A2PRKCA | |
| SCHEMBL4379562 | 0.83 | MEN1 (0.48) | MEN1KMT2ANR4A2PRKCAPRKCD | |
| SCHEMBL4382696 | 0.82 | KMT2A (0.53) | MEN1KMT2APOLBSMN1; SMN2LMNA | |
| SCHEMBL4382633 | 0.82 | MEN1 (0.43) | MEN1KMT2AFAAHNR4A2PRKCA | |
| SCHEMBL8210228 | 0.81 | MEN1 (0.43) | MEN1KMT2ACYP2D6POLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4386259 | 0.81 | MEN1 (0.42) | MEN1KMT2ACYP2D6POLBSMN1; SMN2 | |
| SCHEMBL4380358 | 0.81 | LMNA (0.51) | MEN1KMT2ANR4A2POLBCYP2C19 | |
| SCHEMBL4395452 | 0.80 | FAAH (0.63) | MEN1KMT2AFAAHSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | MEN1 3694/4885KMT2A 2079/4885CACNA1B 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.